{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:03:55Z","timestamp":1792785835400,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hospital Group Twente"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related inflammatory disorders. Easily measurable biomarkers defining active disease and identifying patients in need of glucocorticoid sparing treatment options are highly desired. Interferon Type I (IFN-I) might be involved in disease pathology; however, evidence is limited. This study explores a systemic IFN-I signature and expression of IFN-I markers in GCA and PMR patients. Treatment naive GCA and PMR patients, and PMR patients with glucocorticoid treatment were included. Patients suspected of but not diagnosed with GCA were used as controls. Five relevant IFN-I-stimulated genes were identified in literature, and relative expression levels were determined using quantitative reverse transcription polymerase chain reaction (RT-qPCR) in peripheral blood mononuclear cells. An IFN-I score was generated. Serum levels of IFN-I induced C-X-C motif chemokine 10 (CXCL10) and Galectin-9 were determined by multiplex immunoassay. There were no differences in IFN-I scores between the groups. An IFN-I signature was observed in 0\/9 controls, 2\/11 GCA patients, 4\/20 treatment naive PMR patients, and 2\/10 PMR patients with treatment. Serum CXCL10 and Galectin-9 were not increased in GCA or PMR patients compared to control patients. Treated PMR patients had lower CXCL10 levels [423.2 pg\/ml (375.1\u2013491.1)] compared to treatment naive PMR patients [641.8 pg\/ml (552.8\u2013830.6)]. An IFN-I signature does not distinguish GCA and PMR patients from controls. Also, IFN-I-induced serum markers are not upregulated in GCA and PMR patients. Easily measurable IFN-I-induced serum markers will therefore probably not aid in diagnosis and additional treatment options in newly diagnosed GCA and PMR patients.<\/jats:p>","DOI":"10.1093\/cei\/uxae085","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T07:16:30Z","timestamp":1727939790000},"page":"308-313","source":"Crossref","is-referenced-by-count":5,"title":["Investigating interferon type I responses in patients with suspected giant cell arteritis and polymyalgia rheumatica"],"prefix":"10.1093","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2188-6117","authenticated-orcid":false,"given":"Marieke","family":"van Nieuwland","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Hospital Group Twente (Ziekenhuisgroep Twente) , Almelo ,","place":["The Netherlands"]},{"name":"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A H Leontine","family":"Mulder","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Unilabs Oost , Enschede ,","place":["The Netherlands"]},{"name":"Department of Clinical Chemistry, Hospital Group Twente (Ziekenhuisgroep Twente) , Almelo ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar M","family":"Colin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Hospital Group Twente (Ziekenhuisgroep Twente) , Almelo ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Alves","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Hospital Group Twente (Ziekenhuisgroep Twente) , Almelo ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenny","family":"van Bon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Hospital Group Twente (Ziekenhuisgroep Twente) , Almelo ,","place":["The Netherlands"]},{"name":"Department of Rheumatology, Radboudumc , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-4423","authenticated-orcid":false,"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2024111307581112700_CIT0001","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2024111307581112700_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/EB.S170388","article-title":"Giant cell arteritis: early diagnosis is key","volume":"11","author":"Baig","year":"2019","journal-title":"Eye Brain"},{"key":"2024111307581112700_CIT0003","first-page":"002562","article-title":"A tale of diagnostic delay with detrimental consequences: illustrating the challenging nature of diagnosing giant cell arteritis","volume":"8","author":"van Nieuwland","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"2024111307581112700_CIT0004","doi-asserted-by":"crossref","first-page":"e019320","DOI":"10.1136\/bmjopen-2017-019320","article-title":"Challenges of diagnosis and management of giant cell arteritis in general practice: a multimethods study","volume":"8","author":"Helliwell","year":"2018","journal-title":"BMJ Open"},{"key":"2024111307581112700_CIT0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J Intern Med"},{"key":"2024111307581112700_CIT0006","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"2024111307581112700_CIT0007","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2024111307581112700_CIT0008","doi-asserted-by":"crossref","first-page":"152017","DOI":"10.1016\/j.semarthrit.2022.152017","article-title":"Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data","volume":"55","author":"Hemmig","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024111307581112700_CIT0009","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","article-title":"Disease stratification in GCA and PMR: state of the art and future perspectives","volume":"19","author":"Tomelleri","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024111307581112700_CIT0010","doi-asserted-by":"crossref","first-page":"1202160","DOI":"10.3389\/fimmu.2023.1202160","article-title":"Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants","volume":"14","author":"Carvajal Alegria","year":"2023","journal-title":"Front Immunol"},{"key":"2024111307581112700_CIT0011","doi-asserted-by":"crossref","first-page":"484","DOI":"10.12998\/wjcc.v3.i6.484","article-title":"Giant cell arteritis: current treatment and management","volume":"3","author":"Ponte","year":"2015","journal-title":"World J Clin Cases"},{"key":"2024111307581112700_CIT0012","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/ar1015","article-title":"Microarray analysis of gene expression in lupus","volume":"5","author":"Crow","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"2024111307581112700_CIT0013","doi-asserted-by":"crossref","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2024111307581112700_CIT0014","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024111307581112700_CIT0015","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of Varicella-Zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol."},{"key":"2024111307581112700_CIT0016","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/cells13030267","article-title":"Giant cell arteritis: advances in understanding pathogenesis and implications for clinical practice","volume":"13","author":"Paroli","year":"2024","journal-title":"Cells"},{"key":"2024111307581112700_CIT0017","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/03009740802448841","article-title":"Expression of the class I interferon-related MxA protein in temporal arteries in polymyalgia rheumatica and temporal arteritis","volume":"38","author":"Nordborg","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"2024111307581112700_CIT0018","doi-asserted-by":"crossref","first-page":"1197293","DOI":"10.3389\/fimmu.2023.1197293","article-title":"Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients","volume":"14","author":"van Nieuwland","year":"2023","journal-title":"Front Immunol"},{"key":"2024111307581112700_CIT0019","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2665-9913(21)00254-X","article-title":"The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease","volume":"4","author":"Cooles","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"2024111307581112700_CIT0020","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.2022-0827","article-title":"Type I interferons in autoimmunity: implications in clinical phenotypes and treatment response","volume":"50","author":"Londe","year":"2023","journal-title":"J Rheumatol"},{"key":"2024111307581112700_CIT0021","doi-asserted-by":"crossref","first-page":"e002687","DOI":"10.1136\/rmdopen-2022-002687","article-title":"Interferon signature in systemic autoimmune diseases: what does it mean","volume":"8","author":"Nocturne","year":"2022","journal-title":"RMD Open"},{"key":"2024111307581112700_CIT0022","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3389\/fimmu.2019.01981","article-title":"Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica","volume":"10","author":"van Sleen","year":"2019","journal-title":"Front Immunol"},{"key":"2024111307581112700_CIT0023","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cyto.2017.10.021","article-title":"Effect of anticoagulants on 162 circulating immune related proteins in healthy subjects","volume":"106","author":"Scholman","year":"2018","journal-title":"Cytokine"},{"key":"2024111307581112700_CIT0024","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024111307581112700_CIT0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13075-019-2034-4","article-title":"Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin","volume":"21","author":"Lambers","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024111307581112700_CIT0026","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024111307581112700_CIT0027","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024111307581112700_CIT0028","doi-asserted-by":"crossref","first-page":"102796","DOI":"10.1016\/j.jaut.2022.102796","article-title":"Interferon signature in giant cell arteritis aortitis","volume":"127","author":"Vieira","year":"2022","journal-title":"J Autoimmun"},{"key":"2024111307581112700_CIT0029","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1212\/WNL.0000000000001409","article-title":"Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis","volume":"84","author":"Gilden","year":"2015","journal-title":"Neurology"},{"key":"2024111307581112700_CIT0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/annrheumdis-2016-210152","article-title":"Infections and the risk of incident giant cell arteritis: a population-based, case-control study","volume":"76","author":"Rhee","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024111307581112700_CIT0031","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3389\/fimmu.2017.01377","article-title":"Decreased immunity to Varicella Zoster virus in giant cell arteritis","volume":"8","author":"Rondaan","year":"2017","journal-title":"Front Immunol"},{"key":"2024111307581112700_CIT0032","doi-asserted-by":"crossref","first-page":"e160251","DOI":"10.1172\/jci.insight.160251","article-title":"Glucocorticoids target the CXCL9\/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury","volume":"8","author":"Riedel","year":"2023","journal-title":"JCI Insight"},{"key":"2024111307581112700_CIT0033","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"2024111307581112700_CIT0034","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae085\/59921188\/uxae085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/218\/3\/308\/60630273\/uxae085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/218\/3\/308\/60630273\/uxae085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:20:36Z","timestamp":1731478836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/218\/3\/308\/7810884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,4]]},"published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae085","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,4]]}}}